[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100542420":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":37,"collaborators":39,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":7,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":55,"studyType":56,"phases":7,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Sahajanand Medical Technologies Limited","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DEVICE","Hydra Transcatheter Aortic Valve (THV) Series","The Hydra device consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Dr. Ole De Backer","CONTACT","+4527605009","ole.debacker@gmail.com",[20],{"facility":21,"status":22,"city":23,"state":7,"zip":7,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Copenhagen University Hospital, Rigshospitalet","RECRUITING","Copenhagen","Denmark","DK",{"type":27,"coordinates":28},"Point",[29,30],12.56553,55.67594,{"lat":30,"lon":29},[33,34],{"name":15,"role":16,"phone":7,"phoneExt":7,"email":7},{"name":35,"role":36,"phone":7,"phoneExt":7,"email":7},"Dr. Ole De Backer, Copenhagen University Hospital, Rigshospitalet","PRINCIPAL_INVESTIGATOR",{"type":38,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[40],{"name":41,"class":6},"Qmed Consulting A\u002FS","100542420","hydra-single-centre-experience---copenhagen-denmark-100542420",false,"NCT06342635","Hydra Single-centre Experience - Copenhagen, Denmark","Prospective Observational Single-centre Study on the Efficacy and Safety of Hydra Transcatheter Aortic Valve","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Patients affected by severe aortic stenosis (NYHA class ≥ II) eligible for TAVI procedure as per local Heart Team evaluation\n3. Full understanding and willing to provide informed consent to study enrolment\n\nExclusion Criteria:\n\n1. Contraindications to TAVI (e.g., anatomically phenotypes, intracardiac mass, thrombus, vegetation, endocarditis)\n2. Refusal to provide informed consent to study enrolment\n3. Patients with severe aorta or peripheral artery disease precluding transfemoral approach of TAVI\n4. Patients with calcification on the annulus and in the Left Ventricular Outflow Tract (LVOT), or\u002Fand excess calcium within each cusp, or those who are deemed unsuitable for the Hydra THV series based on the clinical judgment of the Investigator","ALL","18 Years","99 Years",{"count":53,"type":54},50,"ESTIMATED","1 Year","OBSERVATIONAL","The present study aims to evaluate the efficacy and safety of TAVI using the Hydra transcatheter aortic valve (THV) series, in patients with severe aortic stenosis up to 1-year after the procedure. Additionally, the study will assess the role of geometry in the development of new conduction abnormalities based on the analysis of post-operative CT scan at 1-month in patients who had undergone transcatheter aortic valve replacement with a self-expanding Hydra THV series.",[59],"Aortic Valve Stenosis",[59,61,62],"TAVI","Hydra","2026-04-22",{"date":65,"type":66},"2026-04-27","ACTUAL",{"date":68,"type":66},"2024-06-18",{"date":70,"type":54},"2027-10-31",{"name":5,"class":6},1]